<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Rev Bras Ter Intensiva</journal-id><journal-id journal-id-type="iso-abbrev">Rev Bras Ter Intensiva</journal-id><journal-id journal-id-type="publisher-id">rbti</journal-id><journal-title-group><journal-title>Revista Brasileira de Terapia Intensiva</journal-title></journal-title-group><issn pub-type="ppub">0103-507X</issn><issn pub-type="epub">1982-4335</issn><publisher><publisher-name>Associa&#x000e7;&#x000e3;o de Medicina Intensiva Brasileira -
AMIB</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">28977255</article-id><article-id pub-id-type="pmc">5496748</article-id><article-id pub-id-type="doi">10.5935/0103-507X.20170024</article-id><article-categories><subj-group subj-group-type="heading"><subject>Original Articles</subject></subj-group></article-categories><title-group><article-title>Statistical analysis plan for the Alveolar Recruitment for Acute
Respiratory Distress Syndrome Trial (ART). A randomized controlled
trial</article-title><trans-title-group xml:lang="pt"><trans-title>Plano de an&#x000e1;lise estat&#x000ed;stica para o <italic>Alveolar
Recruitment for Acute Respiratory Distress Syndrome Trial</italic>
(ART). Ensaio controlado randomizado</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author"><name><surname>Damiani</surname><given-names>Lucas Petri</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Berwanger</surname><given-names>Otavio</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Paisani</surname><given-names>Denise</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Laranjeira</surname><given-names>Ligia Nasi</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Suzumura</surname><given-names>Erica Aranha</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Amato</surname><given-names>Marcelo Britto Passos</given-names></name><xref ref-type="aff" rid="aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Carvalho</surname><given-names>Carlos Roberto Ribeiro</given-names></name><xref ref-type="aff" rid="aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Cavalcanti</surname><given-names>Alexandre Biasi</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="corresp" rid="c1"/></contrib><on-behalf-of>em nome dos investigadores do ART</on-behalf-of></contrib-group><aff id="aff1"><label>1</label> HCor Research Institute - S&#x000e3;o Paulo (SP), Brasil.</aff><aff id="aff2"><label>2</label> Divis&#x000e3;o de Pneumologia, Instituto do Cora&#x000e7;&#x000e3;o,
Hospital das Cl&#x000ed;nicas, Faculdade de Medicina, Universidade de S&#x000e3;o
Paulo - S&#x000e3;o Paulo (SP), Brasil.</aff><author-notes><corresp id="c1"><bold>Corresponding author:</bold> Alexandre Biasi Cavalcanti,
Instituto de Pesquisa do Hospital do Cora&#x000e7;&#x000e3;o, Rua Ab&#x000ed;lio
Soares, 250, 12&#x000ba; andar, Zip code: 04005-000 - S&#x000e3;o Paulo (SP), Brazil,
E-mail: <email>abiasi@hcor.com.br</email></corresp></author-notes><pub-date pub-type="epub-ppub"><season>Apr-Jun</season><year>2017</year></pub-date><!--Fake ppub date generated by PMC from publisher
							pub-date/@pub-type='epub-ppub' --><pub-date pub-type="ppub"><season>Apr-Jun</season><year>2017</year></pub-date><volume>29</volume><issue>2</issue><fpage>142</fpage><lpage>153</lpage><history><date date-type="received"><day>19</day><month>5</month><year>2017</year></date><date date-type="accepted"><day>01</day><month>6</month><year>2017</year></date></history><permissions><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/4.0/"><license-p>This is an Open Access article distributed under the terms of the
Creative Commons Attribution License, which permits unrestricted use,
distribution, and reproduction in any medium, provided the original work is
properly cited.</license-p></license></permissions><abstract><sec><title>Background</title><p>The Alveolar Recruitment for Acute Respiratory Distress Syndrome Trial (ART)
is an international multicenter randomized pragmatic controlled trial with
allocation concealment involving 120 intensive care units in Brazil,
Argentina, Colombia, Italy, Poland, Portugal, Malaysia, Spain, and Uruguay.
The primary objective of ART is to determine whether maximum stepwise
alveolar recruitment associated with PEEP titration, adjusted according to
the static compliance of the respiratory system (ART strategy), is able to
increase 28-day survival in patients with acute respiratory distress
syndrome compared to conventional treatment (ARDSNet strategy).</p></sec><sec><title>Objective</title><p>To describe the data management process and statistical analysis plan.</p></sec><sec><title>Methods</title><p>The statistical analysis plan was designed by the trial executive committee
and reviewed and approved by the trial steering committee. We provide an
overview of the trial design with a special focus on describing the primary
(28-day survival) and secondary outcomes. We describe our data management
process, data monitoring committee, interim analyses, and sample size
calculation. We describe our planned statistical analyses for primary and
secondary outcomes as well as pre-specified subgroup analyses. We also
provide details for presenting results, including mock tables for baseline
characteristics, adherence to the protocol and effect on clinical
outcomes.</p></sec><sec><title>Conclusion</title><p>According to best trial practice, we report our statistical analysis plan and
data management plan prior to locking the database and beginning analyses.
We anticipate that this document will prevent analysis bias and enhance the
utility of the reported results.</p></sec><sec><title>Trial registration</title><p>ClinicalTrials.gov number, NCT01374022.</p></sec></abstract><trans-abstract xml:lang="pt"><sec><title>Fundamenta&#x000e7;&#x000e3;o</title><p>O estudo <italic>Alveolar Recruitment for Acute Respiratory Distress Syndrome
Trial</italic> (ART) &#x000e9; um ensaio cl&#x000ed;nico internacional,
multic&#x000ea;ntrico, randomizado, pragm&#x000e1;tico e controlado com
oculta&#x000e7;&#x000e3;o da aloca&#x000e7;&#x000e3;o que envolve 120 unidades
de terapia intensiva no Brasil, Argentina, Col&#x000f4;mbia, Espanha,
It&#x000e1;lia, Pol&#x000f4;nia, Portugal, Mal&#x000e1;sia e Uruguai, com o
objetivo prim&#x000e1;rio de determinar se o recrutamento alveolar gradual
m&#x000e1;ximo associado com titula&#x000e7;&#x000e3;o da press&#x000e3;o
positiva expirat&#x000f3;ria final, ajustada segundo a complac&#x000ea;ncia
est&#x000e1;tica do sistema respirat&#x000f3;rio (estrat&#x000e9;gia ART),
&#x000e9; capaz de aumentar, quando comparada aos resultados do tratamento
convencional (estrat&#x000e9;gia ARDSNet), a sobreviv&#x000ea;ncia em 28 dias
de pacientes com s&#x000ed;ndrome do desconforto respirat&#x000f3;rio
agudo.</p></sec><sec><title>Objetivo</title><p>Descrever o processo de gerenciamento dos dados e o plano de an&#x000e1;lise
estat&#x000ed;stica em um ensaio cl&#x000ed;nico internacional.</p></sec><sec><title>M&#x000e9;todos</title><p>O plano de an&#x000e1;lise estat&#x000ed;stica foi delineado pelo comit&#x000ea;
executivo e revisado pelo comit&#x000ea; diretivo do ART. Foi oferecida uma
vis&#x000e3;o geral do delineamento do estudo, com foco especial na
descri&#x000e7;&#x000e3;o de desfechos prim&#x000e1;rio (sobreviv&#x000ea;ncia
aos 28 dias) e secund&#x000e1;rios. Foram descritos o processo de
gerenciamento dos dados, o comit&#x000ea; de monitoramento de dados, a
an&#x000e1;lise interina e o c&#x000e1;lculo do tamanho da amostra.
Tamb&#x000e9;m foram registrados o plano de an&#x000e1;lise estat&#x000ed;stica
para os desfechos prim&#x000e1;rio e secund&#x000e1;rios, e os subgrupos de
an&#x000e1;lise pr&#x000e9;-especificados. Detalhes para
apresenta&#x000e7;&#x000e3;o dos resultados, inclusive modelos de tabelas para
as caracter&#x000ed;sticas basais, ades&#x000e3;o ao protocolo e efeito nos
desfechos cl&#x000ed;nicos, foram fornecidos.</p></sec><sec><title>Conclus&#x000e3;o</title><p>Em acordo com as melhores pr&#x000e1;ticas em ensaios cl&#x000ed;nicos,
submetemos nossos planos de an&#x000e1;lise estat&#x000ed;stica e de
gerenciamento de dados para publica&#x000e7;&#x000e3;o antes do fechamento da
base de dados e in&#x000ed;cio das an&#x000e1;lises. Antecipamos que este
documento deve prevenir vi&#x000e9;s em an&#x000e1;lises e incrementar a
utilidade dos resultados a serem relatados.</p></sec><sec><title>Registro do estudo</title><p>N&#x000fa;mero no registro ClinicalTrials.gov NCT01374022.</p></sec></trans-abstract><kwd-group><kwd>Acute respiratory distress syndrome</kwd><kwd>Positive-pressure respiration</kwd><kwd>Critically ill</kwd></kwd-group></article-meta></front><body><sec sec-type="intro"><title>INTRODUCTION</title><p>Alveolar collapse with reduction of functional lung size ("baby lung") is a hallmark
of acute respiratory distress syndrome (ARDS).<sup>(<xref rid="r1" ref-type="bibr">1</xref>)</sup> Although mechanical ventilation is needed to support life
in patients with moderate-to-severe ARDS, it may damage lungs via two mechanisms:
(1) overdistention and (2) cyclic opening and closing of small airways and alveoli
(atelectrauma).<sup>(<xref rid="r2" ref-type="bibr">2</xref>)</sup>
Mechanical ventilation with low tidal volumes and low positive end-expiratory
pressure (PEEP) decreases but does not eliminate ventilator-induced lung injury
(VILI).<sup>(<xref rid="r3" ref-type="bibr">3</xref>,<xref rid="r4" ref-type="bibr">4</xref>)</sup> Cyclic opening and closing of lung units persists
with this strategy.<sup>(<xref rid="r5" ref-type="bibr">5</xref>)</sup> The aim of
recruitment maneuvers and PEEP titration is to open collapsed units and keep them
open, thus minimizing atelectrauma and possibly dynamic overdistention.<sup>(<xref rid="r6" ref-type="bibr">6</xref>)</sup> Most patients with ARDS for less
than 72 hours are highly responsive to recruitment maneuvers, and serious adverse
events are uncommon.<sup>(<xref rid="r7" ref-type="bibr">7</xref>,<xref rid="r8" ref-type="bibr">8</xref>)</sup> However, the effect of recruitment
maneuvers and PEEP titration on the clinical outcome of ARDS patients is uncertain.
A systematic review with a meta-analysis of studies assessing recruitment maneuvers
suggested a reduction in mortality; however, the quality of evidence is limited due
to the high risk of bias in most primary studies and variable use of
co-interventions, such as PEEP titration.<sup>(<xref rid="r9" ref-type="bibr">9</xref>)</sup></p><p>The Alveolar Recruitment for Acute Respiratory Distress Syndrome Trial (ART) is an
international multicenter randomized controlled trial that compares a strategy for
maximum lung recruitment associated with PEEP titration adjusted according to the
static compliance of the respiratory system to a conventional approach (ARDSNet
protocol) for patients with moderate-severe ARDS.</p><p>This article outlines the statistical analysis plan for ART with the aim of
preventing statistical analysis bias arising from exploratory analyses after the
study results are known. The statistical analysis plan was developed prior to
locking the trial database and starting analyses.</p><p>The primary objective of this study is to determine whether alveolar recruitment
associated with PEEP titration adjusted according to the static compliance of the
respiratory system (ART strategy) increases the 28-day survival rate of patients
with moderate to severe ARDS compared to conventional treatment (ARDSNet
strategy).</p></sec><sec sec-type="methods"><title>METHODS</title><p>ART is an international multicenter randomized pragmatic controlled trial with
allocation concealment and intention-to-treat analysis that compares a strategy of
maximum lung recruitment associated with PEEP titration adjusted according to the
static compliance of the respiratory system (ART strategy) to the ARDSNet approach
for patients with moderate to severe ARDS. The trial is being conducted in 120
intensive care units in Brazil, Argentina, Colombia, Italy, Poland, Portugal,
Malaysia, Spain, and Uruguay. The trial protocol was previously published and is
registered with ClinicalTrials.gov (NCT01374022)<sup>(<xref rid="r10" ref-type="bibr">10</xref>)</sup> and was approved by the Ethics Committee of all
of the participant institutions.</p><p>Eligibility is evaluated in two phases, a screening phase and defining eligibility
phase. In the screening phase, patients are considered for inclusion in the study if
they are receiving invasive mechanical ventilation and have ARDS of less than 72
hours' duration. All of the following criteria should be met: acute onset
respiratory failure; bilateral pulmonary infiltrate on chest X ray that is
compatible with pulmonary edema; severe hypoxemia, defined as a partial pressure of
arterial oxygen to fractional inspired oxygen ratio
(PaO<sub>2</sub>/FIO<sub>2</sub>) &#x02264; 200 in arterial blood gases for less than
72 hours; absence of left atrial hypertension based on the medical team's evaluation
(clinical or echocardiographic signs); and presence of a risk factor for lung
injury. The exclusion criteria (exclusion if anyone is present) are as follows: age
&#x0003c; 18 years; use of vasoconstrictor drugs in increasing doses over the past 2
hours (&#x02265; 0.2mcg/kg per min for norepinephrine or &#x02265; 5mcg/kg per min for
dopamine) or a mean arterial pressure &#x0003c; 65mmHg; contraindication of hypercapnia
with intracranial hypertension or acute coronary syndrome; pneumothorax,
subcutaneous emphysema, pneumomediastinum or pneumatocele; patient with no
therapeutic perspective; candidate for palliative care exclusively (e.g., patient
with imminent death, in moribund state or dying from cancer under exclusive
palliative care); and previously randomized in the study.</p><p>While waiting for consent from a legal representative, we suggest ventilating the
patient using a conventional approach (ARDSNet) as follows: volume-controlled mode,
tidal volume of 4 - 6mL/kg of predicted body weight to ensure a plateau pressure
&#x02264; 30cmH<sub>2</sub>O, PEEP and fractional inspired oxygen (FIO<sub>2</sub>)
adjusted according to the ARDSNet table (<xref ref-type="table" rid="t1">Table
1</xref>) to maintain peripheral oxygen saturation (SpO<sub>2</sub>) &#x02265;
88% and arterial oxygen partial pressure (PaO<sub>2</sub>) &#x02265; 55mmHg, flow of
60L/min (may be reduced if peak pressure &#x0003e; 45cmH<sub>2</sub>O), descending
waveform, inspiratory to expiratory ratio (I:E) of 1:1 to 1:2, inspiratory pause of
0.5 second (may be reduced if I:E ratio is inverted), and respiratory rate to
maintain the partial pressure of carbon dioxide (PaCO<sub>2</sub>) between 35mmHg
and 60mmHg. Alveolar recruitment maneuvers should be avoided.</p><table-wrap id="t1" orientation="portrait" position="float"><label>Table 1</label><caption><p>ARDSNet table of the fraction of inspired oxygen and positive end-expiratory
pressure values to maintain peripheral oxygen saturation &#x02265; 88% and
partial pressure of arterial oxygen &#x02265; 55mmHg</p></caption><table frame="hsides" rules="groups"><colgroup span="1"><col width="6%" span="1"/><col width="6%" span="1"/><col width="6%" span="1"/><col width="6%" span="1"/><col width="6%" span="1"/><col width="6%" span="1"/><col width="6%" span="1"/><col width="6%" span="1"/><col width="6%" span="1"/><col width="6%" span="1"/><col width="6%" span="1"/><col width="6%" span="1"/><col width="6%" span="1"/><col width="6%" span="1"/><col width="6%" span="1"/></colgroup><tbody><tr><td align="left" rowspan="1" colspan="1"><bold>FIO<sub>2</sub> (%)</bold></td><td align="center" rowspan="1" colspan="1">30</td><td align="center" rowspan="1" colspan="1">40</td><td align="center" rowspan="1" colspan="1">40</td><td align="center" rowspan="1" colspan="1">50</td><td align="center" rowspan="1" colspan="1">50</td><td align="center" rowspan="1" colspan="1">60</td><td align="center" rowspan="1" colspan="1">70</td><td align="center" rowspan="1" colspan="1">70</td><td align="center" rowspan="1" colspan="1">70</td><td align="center" rowspan="1" colspan="1">80</td><td align="center" rowspan="1" colspan="1">90</td><td align="center" rowspan="1" colspan="1">90</td><td align="center" rowspan="1" colspan="1">90</td><td align="center" rowspan="1" colspan="1">100</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>PEEP</bold></td><td align="center" rowspan="1" colspan="1">5</td><td align="center" rowspan="1" colspan="1">5</td><td align="center" rowspan="1" colspan="1">8</td><td align="center" rowspan="1" colspan="1">8</td><td align="center" rowspan="1" colspan="1">10</td><td align="center" rowspan="1" colspan="1">10</td><td align="center" rowspan="1" colspan="1">10</td><td align="center" rowspan="1" colspan="1">12</td><td align="center" rowspan="1" colspan="1">14</td><td align="center" rowspan="1" colspan="1">14</td><td align="center" rowspan="1" colspan="1">14</td><td align="center" rowspan="1" colspan="1">16</td><td align="center" rowspan="1" colspan="1">18</td><td align="center" rowspan="1" colspan="1">18-24</td></tr></tbody></table><table-wrap-foot><fn id="TFN10"><p>FIO<sub>2</sub> - fraction of inspired oxygen; PEEP - positive
end-expiratory pressure.</p></fn></table-wrap-foot></table-wrap><p>After three hours of mechanical ventilation according to the ARDSNet protocol,
FIO<sub>2</sub> is adjusted to 100% and PEEP to 10cmH<sub>2</sub>O (except if
PEEP was previously &#x02265; 16cmH<sub>2</sub>O; in this case PEEP is maintained)
for 30 minutes, after which the arterial blood gases are measured. Patients are
considered eligible if the PaO<sub>2</sub> measured with FIO<sub>2</sub> = 100% and
PEEP = 10cmH<sub>2</sub>O (or &#x02265; 16cmH<sub>2</sub>O) is 200mmHg or less, and
less than 72 hours have been spent since the first time
PaO<sub>2</sub>/FIO<sub>2</sub> &#x02264; 200 was determined.</p><sec><title>Randomization</title><p>Eligible patients are randomly allocated in a 1:1 ratio for treatment with either
the ART or ARDSNet strategy. The randomization list is generated electronically
using appropriate software. Randomization is performed in blocks with
stratification by center, age (&#x02264; 55 or &#x0003e; 55 years-old) and
PaO<sub>2</sub>/FIO<sub>2</sub> ratio (&#x02264; 100 or &#x0003e; 100mmHg).</p><p>Allocation concealment is maintained by means of a web-based central automated
randomization system that is available 24 hours a day (ACT-Clinic) and was
developed by a team of programmers and investigators from the Research Institute
HCor. The group to which the patient is allocated is disclosed only after the
patient is registered in the electronic system. This prevents the investigator
and medical team from predicting the treatment group to which the patient will
be allocated. To include a patient in the study, investigators must simply
access the HCor Data Management System website (<ext-link ext-link-type="uri" xlink:href="https://servicos.hcor.com.br/iep/estudoclinico">https://servicos.hcor.com.br/iep/estudoclinico</ext-link>) and fill out a
short medical record form.</p></sec><sec><title>Treatment groups</title><p>Patients randomly assigned to the ART group undergo alveolar recruitment with
incremental PEEP levels, followed by PEEP titration according to the static
compliance of the respiratory system and a new recruitment. After recruitment
and PEEP titration, patients are ventilated in controlled volume mode with PEEP
set at the titrated value for at least 24 hours. <xref ref-type="fig" rid="f1">Figure 1</xref> shows a schematic representation of the recruitment
maneuver followed by PEEP titration.</p><p><fig id="f1" orientation="portrait" position="float"><label>Figura 1</label><caption><p>Schematic representation of the Alveolar Recruitment for ARDS Trial
strategy with the recruitment maneuver and positive end-expiratory
pressure titration according to the static compliance of the
respiratory system.</p></caption><graphic xlink:href="rbti-29-02-0142-g01"/></fig></p><p>The recruitment maneuver and PEEP (positive end-expiratory pressure) titration
are initiated only after a protocolized preparation that included: (1) sedation
and neuromuscular blockade; (2) maintaining patients in the supine or prone
position; (3) aspirating lower airway secretions; (4) installing a closed
tracheal suctioning system as well as a heat and moisture exchanger; (5)
assuring adequate monitoring, including and invasive blood pressure measurement;
(6) correcting hypovolemia; (7) keeping the mean arterial pressure 75mmHg (if
needed by starting or increasing vasopressors); (8) adjusting the respiratory
rate to 35 breaths per minute for at least 20 minutes before recruitment; (9)
disabling back-up or apnea ventilation. The recruitment maneuver is conducted in
controlled pressure mode with a respiratory rate of 15 breaths per minute,
FIO<sub>2</sub>=100%, and inspiratory to expiratory (I:E) ratio of 1:1. PEEP
is set at 25cmH<sub>2</sub>O, with a pressure above PEEP of 15cmH<sub>2</sub>O
for 1 minute. Then, PEEP is increased to 30cmH<sub>2</sub>O for 1 minute and
finally to 35 cmH<sub>2</sub>O. After recruitment, PEEP titration is started
with the following settings: a PEEP of 23cmH<sub>2</sub>O, volume controlled
mode, tidal volume of 5mL/kg of predicted body weight, respiratory rate of 20
breaths per minute, flow of 30 L/min (square wave flow) and
FIO<sub>2</sub>=100%. After 3 minutes, the static compliance of the respiratory
system is calculated (with an inspiratory pause of 2 seconds). Then, PEEP is
reduced by 3cmH<sub>2</sub>Oand maintained for 3 minutes, static compliance is
measured again, and the steps are repeated until a PEEP of 11cmH<sub>2</sub>Ois
reached. The ideal PEEP is the PEEP with the best static compliance of the
respiratory system plus 2cmH<sub>2</sub>O. After PEEP titration, a new
recruitment maneuver is conducted as follows: pressure-controlled mode,
respiratory rate of 15 breaths per minute, FIO<sub>2</sub>=100%, inspiratory to
expiratory (I:E) ratio of 1:1 and PEEP of 35cmH<sub>2</sub>O with a pressure
above PEEP of 15cmH<sub>2</sub>O for 1 minute. Maintenance ventilation with
optimal PEEP is started soon after this last recruitment maneuver.</p><p>In the first version of the protocol, we applied a recruitment maneuver using
pressure controlled ventilation and a driving pressure of 15cmH<sub>2</sub>O. We
started with a PEEP of 25cmH<sub>2</sub>O for 1 minute, followed by a PEEP of
35cmH<sub>2</sub>O (for 1 minute) and 45cmH<sub>2</sub>O (for 2 minutes).
After recruitment, decremental PEEP titration was started with a PEEP of
23cmH<sub>2</sub>O in volume controlled mode and a tidal volume of 5mL/kg of
predicted body weight. PEEP was decreased in steps of 3cmH<sub>2</sub>O to a
minimum of 11cmH<sub>2</sub>O. After 4 minutes in each step, we measured the
static compliance of the respiratory system. The PEEP associated with the best
static compliance of the respiratory system plus 2cmH<sub>2</sub>O was
considered to be the optimal PEEP. After PEEP titration, new recruitment with
pressure controlled ventilation was carried out in one step using a PEEP of
45mH<sub>2</sub>O for 2 minutes. Then, maintenance ventilation was started
in controlled volume mode with a tidal volume of 6mL/kg, using the optimal PEEP.
The tidal volume was decreased to 5mL/kg or 4mL/kg if the plateau pressure
exceeded 30cmH<sub>2</sub>O.</p><p>The steering committee proposed an amendment to the protocol after 3 cases of
resuscitated cardiac arrest occurred in the experimental arm. The investigators
considered that two of the adverse events were likely caused by respiratory
acidosis and one by hemodynamic collapse, all possibly related to study
interventions (recruitment maneuver and PEEP titration). The amendment was aimed
at decreasing the risk of respiratory acidosis and hemodynamic impact of the
recruitment maneuver. The amendment involved the following modifications to the
experimental group protocol: (1) During recruitment, PEEP starts at
25cmH<sub>2</sub>O, then 30cmH<sub>2</sub>O and finally 35cmH<sub>2</sub>O.
The maximum airway pressure reaches 50cmH<sub>2</sub>O (instead of
60cmH<sub>2</sub>O); (2) all of the recruitment steps last for 1 minute,
totaling 3 minutes; (3) the PEEP titration steps are shortened to 3 minutes; and
(4) after PEEP titration, recruitment is repeated with a PEEP of
35cmH<sub>2</sub>O for 1 minute. The steering committee consulted the Data
Monitoring Committee, which agreed with the proposal. The amendment was
implemented in June 18, 2015, starting with the 556<sup>th</sup> patient
enrolled in ART.</p></sec><sec><title>Outcomes</title><p>Our primary outcome is 28-day survival.</p><p>Our secondary outcomes are: the length of intensive care unit (ICU) stay and
hospitalization; ventilator-free days from day 1 until day 28; pneumothorax
requiring drainage within 7 days; barotrauma within 7 days; and ICU, in-hospital
and 6-month survival.</p><p>We consider pneumothorax to be any case requiring a chest tube within 7 days that
is possibly due to barotrauma; that is, we do not consider cases judged to be
clearly caused by invasive procedures, such as a central venous puncture or
thoracocentesis, to be pneumothorax. We consider barotrauma to be any case
within 7 days that displays any pneumothorax, pneumomediastinum, subcutaneous
emphysema or pneumatocele &#x0003e; 2cm detected on image exams between randomization
and 7 days, except those judged to be clearly caused by invasive procedures.</p><p>The trial also has some exploratory outcomes: death with refractory hypoxemia
within 7 days (defined as PaO<sub>2</sub> &#x0003c; 55mmHg in the last arterial blood
gas analysis with FIO<sub>2</sub> = 100%); death with refractory acidosis within
7 days (defined as pH &#x02264; 7.10 in the last arterial blood gas analysis);
death with barotrauma within 7 days; cardiorespiratory arrest (defined as
unexpected cardiac arrest, not due to progressive refractory shock) on day 1;
need for commencement/increase of vasopressors or hypotension (mean arterial
pressure &#x0003c; 65mmHg) within 1 hour after randomization; refractory hypoxemia
(PaO<sub>2</sub> &#x0003c; 55mmHg) within 1h after randomization; and severe
acidosis (pH &#x0003c; 7.10) within 1h after randomization.</p></sec><sec><title>Data management</title><p>The objective of our clinical data management plan is to provide high-quality
data by adopting standardized procedures to minimize the number of errors and
missing data, and consequently, to generate an accurate database for
analysis.</p></sec><sec><title>Responsibilities</title><p>The principal investigator at each center leads and/or supervises the daily
operation of the project at his/her participating center and may appoint a
Co-investigator and Research Coordinator. Most tasks can be delegated by the
Principal Investigator to research professionals at the Participating Center
provided that the professionals are qualified for such tasks and that the
delegation is clearly recorded with the name of the professional and their role.
However, the principal investigator is legally responsible for the study. The
principal investigator is responsible for ensuring that the data are properly
collected and entered into the Study Data Management System.</p><p>The Research Institute HCor assigns a coordinating team that includes a qualified
data manager who is responsible for guaranteeing the data's accuracy during the
process of data collection and analysis.</p></sec><sec><title>Data collection</title><p>Data collection is performed using electronic case report forms via the Internet
at the HCor Data Management System. The system has the following functions:
patient registration, 24-hour randomization with allocation concealment, data
input, data cleaning, and data export for statistical analysis. Data are entered
directly into the system by each center team. All forms are electronically
signed by the Principal Investigator of each center or by other appointed
persons. Instructions for using the system will be made available to
investigators.</p></sec><sec><title>Quality assurance</title><p>Several strategies are performed to generate completeness and correctness of the
clinical data. Investigators attended a training session before the start of the
study to standardize procedures, including data collection. Study support
material is available at all sites, and the investigators may contact the Study
Coordinating Center to solve issues or problems that may arise.</p><p>Several problems can be detected by the system at the time of data entry.
Subsequently, data monitoring is performed by a data management team in the
central office that looks for missing data and inconsistencies using routines
implemented in R software. In this sense, missing, inconsistent, illogical, out
of range and discrepant data will be marked, and the participating sites will be
notified for corrections or justifications. Weekly reports listing incomplete
follow-up data and inconsistencies are referred to the sites. Resolution of
queries by the investigator is updated in the database. If the investigator
cannot provide a resolution, the reasons are collected in a spreadsheet.
Finally, HCor staff contact all patients discharged alive from the hospital or
their relatives to ensure that the reported 6-month follow-up vital status is
accurate.</p><p>The data management team is also responsible for helping to detect cases of
protocol deviation. When these situations occur, we program new training
sessions at the site to revise the protocol. In addition, the data manager
provides prospective reminders and protocol summaries by email regarding queries
that are frequently detected.</p></sec><sec><title>Database locking</title><p>The database will be locked as soon as all data are entered and all discrepant or
missing data are resolved in the database or if all efforts are employed and we
consider that the remaining issues cannot be fixed. At this step, our
statisticians will review the data before database locking. We will fill out a
database lock checklist before locking the database to ensure the completion of
activities. After that, the study database will be locked and exported for
statistical analysis. At this stage, permission to access the study database
will be removed and the database will be archived.</p></sec><sec><title>Storage and backup</title><p>Electronic files are archived in the HCor Server in a secure and controlled
environment to maintain confidentiality. Electronic documents are controlled
with password protection according to best practices.</p></sec><sec><title>Trial organization and funding</title><p>The Research Institute Hcor is the sponsor and coordinator of the study. The
Research Institute Hcor is primarily responsible for generating the
randomization scheme and study database as well as for performing data quality
assurance and data analysis. The trial structure includes the following groups:
the coordinating center, the investigators, a steering committee and a data
monitoring committee. The trial is endorsed by the Brazilian Research in
Intensive Care Network (BRICNet).</p><p>The trial also receives institutional support from the Brazilian Association of
Intensive Care Medicine (<italic>Associa&#x000e7;&#x000e3;o de Medicina Intensiva
Brasileira</italic> - AMIB) by means of its research network, AMIBNet.</p><p>The study is conducted as part of and funded by the Program to Support
Institutional Development of the Universal Health System (PROADI-SUS) from the
Brazilian Ministry of Health. The funding sources have no role in the design,
execution, analysis, or decision to publish the results.</p></sec><sec><title>Data monitoring committee and interim analyses</title><p>A Data Monitoring Committee (DMC) was established that included an independent
epidemiologist, intensivist, and statistician in 2012 soon after the trial
started. The responsibilities of the DMC are first to help ensure the safety of
patients in the trial by protecting them from avoidable harm. Second, DMC
provides the Steering Committee with advice about the conduct of the trial and
integrity of the data to protect the validity and scientific credibility of the
trial. However, the role of the DMC is limited on this issue because their
detailed review of the progress of the trial only occurs infrequently. Third,
the DMC evaluates interim analyses and judges efficacy, harm, and the net
clinical effect.</p><p>Interim analyses to evaluate primary and secondary endpoints were conducted by an
independent statistician and sent to the DMC after recruitment of approximately
33% and 66% of the sample, that is, when 172 and 344 deaths within 28 days had
occurred. Based on these interim analyses, and possibly on external evidence,
the DMC decided whether there was evidence beyond a reasonable doubt that the
treatment was clearly contraindicated in all patients or any subgroup. The
criterion for evidence beyond a reasonable doubt was increased mortality at 28
days with the maximum lung recruitment strategy compared with the low PEEP
strategy, p &#x0003c; 0.01. Otherwise, the steering committee and other investigators
were not informed of the results of the interim analyses. The two interim
analyses were conducted, and the DMC recommended that the trial continue.</p><p>Considering previous evidence showing that: (1) early discontinuation of
randomized trials due to benefits tends to produce biased estimates of effect
(overestimation of the true effect), leading to erroneous medical guidelines and
decisions; (2) according to the ethical principle of non-maleficence, a new
treatment should not be used until there is clear objective evidence that it is
beneficial; and (3) clinical practice usually does not change unless there is
fairly convincing evidence of the advantages of a new treatment, which would be
undermined if the study is discontinued early due to benefits, early
discontinuation of an experimental treatment due to benefits may not be
advantageous for future patients or may contribute to misleading guidelines. For
these reasons, early discontinuation of the study due to the benefits of the
experimental treatment was not planned.</p><p>Apart from conducting interim analyses of the primary and secondary outcomes, the
DMC also received periodic reports (after multiples of 100 patients were
enrolled) on the incidence of the following study adverse events: (1) need to
interrupt alveolar recruitment maneuver and reasons (heart rate &#x0003e; 150bpm or
&#x0003c; 60bpm; reduction of mean blood pressure to &#x0003c; 65mmHg or systolic blood
pressure &#x0003c; 90mmHg; reduction of SpO<sub>2</sub> &#x0003c; 88% for &#x0003e; 30 seconds;
severe arrhythmia: acute atrial fibrillation or flutter, ventricular
tachycardia); (2) hypotension (mean blood pressure &#x0003c; 65mmHg) within one hour
after randomization; (3) use of vasopressors (norepinephrine or dopamine) within
one hour; (4) hypotension or need for vasopressors within one hour; (5)
hypoxemia (PaO<sub>2</sub> &#x0003c; 55mmHg) within one hour; (6) severe acidosis (pH
&#x0003c; 7.10) within one hour; (7) pneumothorax requiring drainage in the first 7
days after randomization; and (8) any barotrauma in the first 7 days after
randomization. The Coordinating Centre also sent reports of serious
study-related adverse events to the DMC immediately after receiving them.</p></sec><sec><title>Sample size</title><p>ART is an event-driven study designed to last until 520 events (death within 28
days) are observed. This number of events is sufficient to detect a hazard ratio
of 0.75 (i.e., relative reduction in event rate of 25%), considering a type I
error of 5%, 90% power, and similar allocation of subjects to each group.</p><p>An important advantage of using an event-driven strategy is that it ensures
adequate power for the study as well as recruitment of an adequate number of
patients - if the event rate turns out to be higher than that reported in the
literature, the study will be completed with a smaller sample size than would be
required by a method based on the total sample size; consequently, there is no
unnecessary inclusion of patients. If the event rate turns out to be lower than
that reported in the literature, the study is not interrupted before it has
adequate power, as might be the case if the total sample size method was
used.</p></sec><sec><title>Statistical analysis</title><p>All statistical analyses will be conducted according to the intention-to-treat
principle. Thus, patients will be analyzed according to the arm to which they
were allocated (ART or ARDSNet).</p><p>Continuous distribution of the data will be assessed by visual inspection of
histograms and D'Agostino-Pearson's normality tests. For the experimental and
control arms, the baseline characteristics will be expressed as counts and
percentages, means and standard deviations (SD), or medians and interquartile
ranges (IQR) whenever appropriate as indicated in mock <xref ref-type="table" rid="t2">tables 2</xref> to <xref ref-type="table" rid="t6">6</xref>, which
we intend to include in the main results paper.</p><table-wrap id="t2" orientation="portrait" position="float"><label>Table 2</label><caption><p>Baseline characteristics of the patients</p></caption><table frame="hsides" rules="groups"><colgroup span="1"><col width="33%" span="1"/><col width="33%" span="1"/><col width="33%" span="1"/></colgroup><thead><tr><th align="left" rowspan="1" colspan="1">Characteristic</th><th align="center" rowspan="1" colspan="1">ART</th><th align="center" rowspan="1" colspan="1">ARDSNet</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Age (years)</td><td align="center" rowspan="1" colspan="1">xx.x &#x000b1; xx.x</td><td align="center" rowspan="1" colspan="1">xx.x &#x000b1; xx.x</td></tr><tr><td align="left" rowspan="1" colspan="1">Female sex, N/total N (%)</td><td align="center" rowspan="1" colspan="1">x/x (xx.x)</td><td align="center" rowspan="1" colspan="1">x/x (xx.x)</td></tr><tr><td align="left" rowspan="1" colspan="1">SAPS3 score</td><td align="center" rowspan="1" colspan="1">xx.x &#x000b1; xx.x</td><td align="center" rowspan="1" colspan="1">xx.x &#x000b1; xx.x</td></tr><tr><td align="left" rowspan="1" colspan="1">No. of non-pulmonary organ failures</td><td align="center" rowspan="1" colspan="1">xx.x &#x000b1; xx.x</td><td align="center" rowspan="1" colspan="1">xx.x &#x000b1; xx.x</td></tr><tr><td align="left" rowspan="1" colspan="1">Septic shock, N/total N (%)</td><td align="center" rowspan="1" colspan="1">x/x (xx.x)</td><td align="center" rowspan="1" colspan="1">x/x (xx.x)</td></tr><tr><td align="left" rowspan="1" colspan="1">Cause of ARDS</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td></tr><tr><td align="left" rowspan="1" colspan="1">Pulmonary ARDS, N/total N (%)</td><td align="center" rowspan="1" colspan="1">x/x (xx.x)</td><td align="center" rowspan="1" colspan="1">x/x (xx.x)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;Pneumonia</td><td align="center" rowspan="1" colspan="1">x/x (xx.x)</td><td align="center" rowspan="1" colspan="1">x/x (xx.x)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;Gastric aspiration</td><td align="center" rowspan="1" colspan="1">x/x (xx.x)</td><td align="center" rowspan="1" colspan="1">x/x (xx.x)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;Lung contusion</td><td align="center" rowspan="1" colspan="1">x/x (xx.x)</td><td align="center" rowspan="1" colspan="1">x/x (xx.x)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;Near drowning</td><td align="center" rowspan="1" colspan="1">x/x (xx.x)</td><td align="center" rowspan="1" colspan="1">x/x (xx.x)</td></tr><tr><td align="left" rowspan="1" colspan="1">Extrapulmonary ARDS, N/total N (%)</td><td align="center" rowspan="1" colspan="1">x/x (xx.x)</td><td align="center" rowspan="1" colspan="1">x/x (xx.x)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;Non-septic shock</td><td align="center" rowspan="1" colspan="1">x/x (xx.x)</td><td align="center" rowspan="1" colspan="1">x/x (xx.x)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;Sepsis/septic shock</td><td align="center" rowspan="1" colspan="1">x/x (xx.x)</td><td align="center" rowspan="1" colspan="1">x/x (xx.x)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;Trauma without lung contusion</td><td align="center" rowspan="1" colspan="1">x/x (xx.x)</td><td align="center" rowspan="1" colspan="1">x/x (xx.x)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;Cardiac surgery</td><td align="center" rowspan="1" colspan="1">x/x (xx.x)</td><td align="center" rowspan="1" colspan="1">x/x (xx.x)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;Other major surgery</td><td align="center" rowspan="1" colspan="1">x/x (xx.x)</td><td align="center" rowspan="1" colspan="1">x/x (xx.x)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;Head trauma</td><td align="center" rowspan="1" colspan="1">x/x (xx.x)</td><td align="center" rowspan="1" colspan="1">x/x (xx.x)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;Smoke inhalation</td><td align="center" rowspan="1" colspan="1">x/x (xx.x)</td><td align="center" rowspan="1" colspan="1">x/x (xx.x)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;Multiple transfusions</td><td align="center" rowspan="1" colspan="1">x/x (xx.x)</td><td align="center" rowspan="1" colspan="1">x/x (xx.x)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;Drug or alcohol abuse</td><td align="center" rowspan="1" colspan="1">x/x (xx.x)</td><td align="center" rowspan="1" colspan="1">x/x (xx.x)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;Other</td><td align="center" rowspan="1" colspan="1">x/x (xx.x)</td><td align="center" rowspan="1" colspan="1">x/x (xx.x)</td></tr><tr><td align="left" rowspan="1" colspan="1">Prone position, N/total N (%)</td><td align="center" rowspan="1" colspan="1">x/x (xx.x)</td><td align="center" rowspan="1" colspan="1">x/x (xx.x)</td></tr><tr><td align="left" rowspan="1" colspan="1">Time since onset of ARDS (hours)</td><td align="center" rowspan="1" colspan="1">x/x (xx.x)</td><td align="center" rowspan="1" colspan="1">x/x (xx.x)</td></tr><tr><td align="left" rowspan="1" colspan="1">Days intubated prior to randomization, median
(IQR)</td><td align="center" rowspan="1" colspan="1">x/x (xx.x)</td><td align="center" rowspan="1" colspan="1">x/x (xx.x)</td></tr><tr><td align="left" rowspan="1" colspan="1">Respiratory measures</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;PaO<sub>2</sub> at FIO<sub>2</sub>=1</td><td align="center" rowspan="1" colspan="1">xx.x &#x000b1; xx.x</td><td align="center" rowspan="1" colspan="1">xx.x &#x000b1; xx.x</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;Tidal volume (mL/kg predicted body weight)</td><td align="center" rowspan="1" colspan="1">xx.x &#x000b1; xx.x</td><td align="center" rowspan="1" colspan="1">xx.x &#x000b1; xx.x</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;Plateau airway pressure (cmH<sub>2</sub>O)</td><td align="center" rowspan="1" colspan="1">xx.x &#x000b1; xx.x</td><td align="center" rowspan="1" colspan="1">xx.x &#x000b1; xx.x</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;Minute ventilation (L/min)</td><td align="center" rowspan="1" colspan="1">xx.x &#x000b1; xx.x</td><td align="center" rowspan="1" colspan="1">xx.x &#x000b1; xx.x</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;Respiratory rate (breaths/min)</td><td align="center" rowspan="1" colspan="1">xx.x &#x000b1; xx.x</td><td align="center" rowspan="1" colspan="1">xx.x &#x000b1; xx.x</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;Driving pressure</td><td align="center" rowspan="1" colspan="1">xx.x &#x000b1; xx.x</td><td align="center" rowspan="1" colspan="1">xx.x &#x000b1; xx.x</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;Positive end-expiratory pressure
(cmH<sub>2</sub>O)</td><td align="center" rowspan="1" colspan="1">xx.x &#x000b1; xx.x</td><td align="center" rowspan="1" colspan="1">xx.x &#x000b1; xx.x</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;Respiratory system static compliance
(mL/cmH<sub>2</sub>O)</td><td align="center" rowspan="1" colspan="1">xx.x &#x000b1; xx.x</td><td align="center" rowspan="1" colspan="1">xx.x &#x000b1; xx.x</td></tr></tbody></table><table-wrap-foot><fn id="TFN11"><p>ART - Alveolar Recruitment Trial; SAPS - Simplified Acute Physiology
Score; ARDS - acute respiratory distress syndrome; PaO<sub>2</sub> -
partial pressure of arterial oxygen; FIO<sub>2</sub> - fraction of
inspired oxygen. Plus-minus values are the means &#x000b1; standard
deviation.</p></fn></table-wrap-foot></table-wrap><table-wrap id="t6" orientation="portrait" position="float"><label>Table 6</label><caption><p>Outcomes</p></caption><table frame="hsides" rules="groups"><colgroup span="1"><col width="20%" span="1"/><col width="20%" span="1"/><col width="20%" span="1"/><col width="20%" span="1"/><col width="20%" span="1"/></colgroup><thead><tr><th align="left" rowspan="1" colspan="1">Outcome</th><th align="center" rowspan="1" colspan="1">ART</th><th align="center" rowspan="1" colspan="1">ARDSNet</th><th align="center" rowspan="1" colspan="1">Hazard ratio<break/> (95%CI)</th><th align="center" rowspan="1" colspan="1">p value</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Primary outcome</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;Death within 28 days, N events/N total (%)</td><td align="center" rowspan="1" colspan="1">x/x (xx.x)</td><td align="center" rowspan="1" colspan="1">x/x (xx.x)</td><td align="center" rowspan="1" colspan="1">x.xx (x.xx - x.xx)</td><td align="center" rowspan="1" colspan="1">x.xx</td></tr><tr><td align="left" rowspan="1" colspan="1">Secondary outcomes</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;Death in hospital, N events/N total (%)<xref ref-type="table-fn" rid="TFN17">*</xref></td><td align="center" rowspan="1" colspan="1">x/x (xx.x)</td><td align="center" rowspan="1" colspan="1">x/x (xx.x)</td><td align="center" rowspan="1" colspan="1">x.xx (x.xx - x.xx)<xref ref-type="table-fn" rid="TFN17">*</xref></td><td align="center" rowspan="1" colspan="1">x.xx</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;Death in intensive care unit, N events/N total
(%)<xref ref-type="table-fn" rid="TFN17">*</xref></td><td align="center" rowspan="1" colspan="1">x/x (xx.x)</td><td align="center" rowspan="1" colspan="1">x/x (xx.x)</td><td align="center" rowspan="1" colspan="1">x.xx (x.xx - x.xx)<xref ref-type="table-fn" rid="TFN17">*</xref></td><td align="center" rowspan="1" colspan="1">x.xx</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;Death within 6 months, N events/N total
(%)</td><td align="center" rowspan="1" colspan="1">x/x (xx.x)</td><td align="center" rowspan="1" colspan="1">x/x (xx.x)</td><td align="center" rowspan="1" colspan="1">x.xx (x.xx - x.xx)</td><td align="center" rowspan="1" colspan="1">x.xx</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;Length of intensive care unit stay (days)<xref ref-type="table-fn" rid="TFN18">&#x02020;</xref></td><td align="center" rowspan="1" colspan="1">xx.x &#x000b1; xx.x</td><td align="center" rowspan="1" colspan="1">xx.x &#x000b1; xx.x</td><td align="center" rowspan="1" colspan="1">x.xx (x.xx - x.xx)<xref ref-type="table-fn" rid="TFN18">&#x02020;</xref></td><td align="center" rowspan="1" colspan="1">x.xx</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;median (IQR)</td><td align="center" rowspan="1" colspan="1">xx (xx to xx)</td><td align="center" rowspan="1" colspan="1">xx (xx to xx)</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;Length of hospital stay (days)<xref ref-type="table-fn" rid="TFN18">&#x02020;</xref></td><td align="center" rowspan="1" colspan="1">xx.x &#x000b1; xx.x</td><td align="center" rowspan="1" colspan="1">xx.x &#x000b1; xx.x</td><td align="center" rowspan="1" colspan="1">x.xx (x.xx - x.xx)<xref ref-type="table-fn" rid="TFN18">&#x02020;</xref></td><td align="center" rowspan="1" colspan="1">x.xx</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;median (IQR)</td><td align="center" rowspan="1" colspan="1">xx (xx to xx)</td><td align="center" rowspan="1" colspan="1">xx (xx to xx)</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;No. of ventilator-free days from day 1 to day
28<xref ref-type="table-fn" rid="TFN18">&#x02020;</xref></td><td align="center" rowspan="1" colspan="1">xx.x &#x000b1; xx.x</td><td align="center" rowspan="1" colspan="1">xx.x &#x000b1; xx.x</td><td align="center" rowspan="1" colspan="1">x.xx (x.xx - x.xx)<xref ref-type="table-fn" rid="TFN18">&#x02020;</xref></td><td align="center" rowspan="1" colspan="1">x.xx</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;median (IQR)</td><td align="center" rowspan="1" colspan="1">xx (xx to xx)</td><td align="center" rowspan="1" colspan="1">xx (xx to xx)</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;Pneumothorax requiring drainage within 7 days,
N events/N total (%)<xref ref-type="table-fn" rid="TFN17">*</xref></td><td align="center" rowspan="1" colspan="1">x/x (xx.x)</td><td align="center" rowspan="1" colspan="1">x/x (xx.x)</td><td align="center" rowspan="1" colspan="1">x.xx (x.xx - x.xx)<xref ref-type="table-fn" rid="TFN17">*</xref></td><td align="center" rowspan="1" colspan="1">x.xx</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;Barotrauma within 7 days, N events/N total
(%)<xref ref-type="table-fn" rid="TFN18">&#x02020;</xref><xref ref-type="table-fn" rid="TFN17">*</xref></td><td align="center" rowspan="1" colspan="1">x/x (xx.x)</td><td align="center" rowspan="1" colspan="1">x/x (xx.x)</td><td align="center" rowspan="1" colspan="1">x.xx (x.xx - x.xx)<xref ref-type="table-fn" rid="TFN17">*</xref></td><td align="center" rowspan="1" colspan="1">x.xx</td></tr><tr><td align="left" rowspan="1" colspan="1">Exploratory outcomes</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;Death with refractory hypoxemia within 7 days,
N events/N total (%)<xref ref-type="table-fn" rid="TFN17">*</xref></td><td align="center" rowspan="1" colspan="1">x/x (xx.x)</td><td align="center" rowspan="1" colspan="1">x/x (xx.x)</td><td align="center" rowspan="1" colspan="1">x.xx (x.xx - x.xx)<xref ref-type="table-fn" rid="TFN17">*</xref></td><td align="center" rowspan="1" colspan="1">x.xx</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;Death with refractory acidosis within 7 days, N
events/N total (%)<xref ref-type="table-fn" rid="TFN17">*</xref></td><td align="center" rowspan="1" colspan="1">x/x (xx.x)</td><td align="center" rowspan="1" colspan="1">x/x (xx.x)</td><td align="center" rowspan="1" colspan="1">x.xx (x.xx - x.xx)<xref ref-type="table-fn" rid="TFN17">*</xref></td><td align="center" rowspan="1" colspan="1">x.xx</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;Death with barotrauma within 7 days, N events/N
total (%)<xref ref-type="table-fn" rid="TFN17">*</xref></td><td align="center" rowspan="1" colspan="1">x/x (xx.x)</td><td align="center" rowspan="1" colspan="1">x/x (xx.x)</td><td align="center" rowspan="1" colspan="1">x.xx (x.xx - x.xx)<xref ref-type="table-fn" rid="TFN17">*</xref></td><td align="center" rowspan="1" colspan="1">x.xx</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;Cardiorespiratory arrest on day 1, N events/N
total (%)<xref ref-type="table-fn" rid="TFN17">*</xref></td><td align="center" rowspan="1" colspan="1">x/x (xx.x)</td><td align="center" rowspan="1" colspan="1">x/x (xx.x)</td><td align="center" rowspan="1" colspan="1">x.xx (x.xx - x.xx)<xref ref-type="table-fn" rid="TFN17">*</xref></td><td align="center" rowspan="1" colspan="1">x.xx</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;Need for commencement/increase of vasopressors
or hypotension (MAP &#x0003c; 65mmHg) within 1 hour<xref ref-type="table-fn" rid="TFN17">*</xref></td><td align="center" rowspan="1" colspan="1">x/x (xx.x)</td><td align="center" rowspan="1" colspan="1">x/x (xx.x)</td><td align="center" rowspan="1" colspan="1">x.xx (x.xx - x.xx)<xref ref-type="table-fn" rid="TFN17">*</xref></td><td align="center" rowspan="1" colspan="1">x.xx</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;Refractory hypoxemia (PaO<sub>2</sub> &#x0003c;
55mmHg) within 1 hour, N (%)<xref ref-type="table-fn" rid="TFN17">*</xref></td><td align="center" rowspan="1" colspan="1">x/x (xx.x)</td><td align="center" rowspan="1" colspan="1">x/x (xx.x)</td><td align="center" rowspan="1" colspan="1">x.xx (x.xx - x.xx)<xref ref-type="table-fn" rid="TFN17">*</xref></td><td align="center" rowspan="1" colspan="1">x.xx</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;Severe acidosis (pH &#x0003c; 7.10) within 1 hour, N
(%)<xref ref-type="table-fn" rid="TFN17">*</xref></td><td align="center" rowspan="1" colspan="1">x/x (xx.x)</td><td align="center" rowspan="1" colspan="1">x/x (xx.x)</td><td align="center" rowspan="1" colspan="1">x.xx (x.xx - x.xx)<xref ref-type="table-fn" rid="TFN17">*</xref></td><td align="center" rowspan="1" colspan="1">x.xx</td></tr></tbody></table><table-wrap-foot><fn id="TFN16"><p>ART - Alveolar Recruitment Trial; 95%CI - 95% confidence interval;
MAP - mean arterial pressure; PaO<sub>2</sub> - partial pressure of
arterial oxygen.</p></fn><fn id="TFN17"><label>*</label><p>Effect estimates are the risk ratios.</p></fn><fn id="TFN18"><label>&#x02020;</label><p>Effect estimates are the mean difference.</p></fn></table-wrap-foot></table-wrap><p>Hypothesis tests will be two-sided with a significance level of 5%. We will not
adjust p values for multiple comparisons. Analyses will be performed using the R
(R Core Team, 2016, Vienna, Austria) program.</p></sec><sec><title>Trial profile</title><p>Patient flow will be presented as a Consolidated Standards of Reporting Trials
diagram (<xref ref-type="fig" rid="f2">Figure 2</xref>).</p><p><fig id="f2" orientation="portrait" position="float"><label>Figura 2</label><caption><p>Study flow.</p><p>MAP - mean arterial pressure; ARDS - acute respiratory distress
syndrome; PaO<sub>2</sub> - partial pressure of arterial oxygen;
FIO<sub>2</sub> - fraction of inspired oxygen; ART - Alveolar
Recruitment for ARDS Trial.</p></caption><graphic xlink:href="rbti-29-02-0142-g02"/></fig></p></sec><sec><title>Baseline comparisons</title><p>We will present patients' baseline characteristics by study arm, as depicted in
<xref ref-type="table" rid="t2">table 2</xref>.</p></sec><sec><title>Adherence to study interventions, respiratory variables</title><p>We will report data to assess adherence to the components of the recruitment
maneuver and PEEP titration procedure, as shown in <xref ref-type="table" rid="t3">table 3</xref>, as well as respiratory variables from hour 1 to day
7 for both arms, as shown in <xref ref-type="table" rid="t4">table 4</xref>.
Fluid balance, weight gain and co-interventions during the first seven days of
treatment will also be presented, as depicted in <xref ref-type="table" rid="t5">table 5</xref>.</p><table-wrap id="t3" orientation="portrait" position="float"><label>Table 3</label><caption><p>Maximum alveolar recruitment maneuver and titrated PEEP levels</p></caption><table frame="hsides" rules="groups"><colgroup span="1"><col width="50%" span="1"/><col width="50%" span="1"/></colgroup><thead><tr><th align="left" rowspan="1" colspan="1">Characteristic</th><th align="center" rowspan="1" colspan="1">ART</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Maximum alveolar recruitment maneuver, N (%)</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;Completed (PEEP = 45cmH<sub>2</sub>O)</td><td align="center" rowspan="1" colspan="1">x/x (x.x)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;Completed (PEEP = 35cmH<sub>2</sub>O)</td><td align="center" rowspan="1" colspan="1">x/x (x.x)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;Interrupted at PEEP = 45cmH<sub>2</sub>O</td><td align="center" rowspan="1" colspan="1">x/x (x.x)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;Interrupted at PEEP = 35cmH<sub>2</sub>O</td><td align="center" rowspan="1" colspan="1">x/x (x.x)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;Interrupted at PEEP = 30cmH<sub>2</sub>O</td><td align="center" rowspan="1" colspan="1">x/x (x.x)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;Interrupted at PEEP = 25cmH<sub>2</sub>O</td><td align="center" rowspan="1" colspan="1">x/x (x.x)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;Interrupted at other PEEP levels</td><td align="center" rowspan="1" colspan="1">x/x (x.x)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;Not attempted</td><td align="center" rowspan="1" colspan="1">x/x (x.x)</td></tr><tr><td align="left" rowspan="1" colspan="1">Neuromuscular blocking agent immediately before
alveolar recruitment maneuver, N (%)</td><td align="center" rowspan="1" colspan="1">x/x (x.x)</td></tr><tr><td align="left" rowspan="1" colspan="1">Volemia optimized before alveolar recruitment
maneuver, N (%)<xref ref-type="table-fn" rid="TFN13">*</xref></td><td align="center" rowspan="1" colspan="1">x/x (x.x)</td></tr><tr><td align="left" rowspan="1" colspan="1">Reason for interrupting alveolar recruitment
maneuver, N (%)</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;Heart rate &#x0003c; 60bpm or &#x0003e; 150bpm</td><td align="center" rowspan="1" colspan="1">x/x (x.x)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;Mean blood pressure &#x0003c; 65mmHg or systolic
blood pressure &#x0003c; 90mmHg</td><td align="center" rowspan="1" colspan="1">x/x (x.x)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;SpO<sub>2</sub> &#x0003c; 88% for longer than
30s</td><td align="center" rowspan="1" colspan="1">x/x (x.x)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;Other</td><td align="center" rowspan="1" colspan="1">x/x (x.x)</td></tr><tr><td align="left" rowspan="1" colspan="1">Titrated PEEP (cmH<sub>2</sub>O)</td><td align="center" rowspan="1" colspan="1">xx.x &#x000b1; xx.x</td></tr><tr><td align="left" rowspan="1" colspan="1">Alveolar recruitment maneuver repeated immediately
after PEEP titration, N (%)</td><td align="center" rowspan="1" colspan="1">x/x (x.x)</td></tr><tr><td align="left" rowspan="1" colspan="1">Recruitment maneuver repeated on days 1 to 7, N
(%)</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;No</td><td align="center" rowspan="1" colspan="1">x/x (x.x)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;Once</td><td align="center" rowspan="1" colspan="1">x/x (x.x)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;Twice</td><td align="center" rowspan="1" colspan="1">x/x (x.x)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;Three or more times</td><td align="center" rowspan="1" colspan="1">x/x (x.x)</td></tr></tbody></table><table-wrap-foot><fn id="TFN12"><p>ART - Alveolar Recruitment Trial; PEEP - positive end-expiratory
pressure; SpO<sub>2</sub> - peripheral oxygen saturation.</p></fn><fn id="TFN13"><label>*</label><p>Volemia is considered optimized when fluids are administered before
recruitment maneuver if dynamic signs of fluid responsiveness are
present (such as pulse pressure variation &#x0003e;13%) or central venous
pressure &#x0003c; 10cmH<sub>2</sub>O. Plus-minus values are the means
&#x000b1; standard deviation.</p></fn></table-wrap-foot></table-wrap><table-wrap id="t4" orientation="portrait" position="float"><label>Table 4</label><caption><p>Respiratory variables during the first seven days of treatment</p></caption><table frame="hsides" rules="groups"><colgroup span="1"><col width="7%" span="1"/><col width="7%" span="1"/><col width="7%" span="1"/><col width="7%" span="1"/><col width="7%" span="1"/><col width="7%" span="1"/><col width="7%" span="1"/><col width="7%" span="1"/><col width="7%" span="1"/><col width="7%" span="1"/><col width="7%" span="1"/><col width="7%" span="1"/><col width="7%" span="1"/></colgroup><thead><tr><th align="left" rowspan="2" colspan="1"> Variable</th><th align="center" colspan="3" rowspan="1">1 hour</th><th align="center" colspan="3" rowspan="1">Day 1</th><th align="center" colspan="3" rowspan="1">Day 3</th><th align="center" colspan="3" rowspan="1">Day 7</th></tr><tr><th align="left" rowspan="1" colspan="1">ART</th><th align="center" rowspan="1" colspan="1">ARDSNet</th><th align="center" rowspan="1" colspan="1">p value</th><th align="center" rowspan="1" colspan="1">ART</th><th align="center" rowspan="1" colspan="1">ARDSNet</th><th align="center" rowspan="1" colspan="1">p value</th><th align="center" rowspan="1" colspan="1">ART</th><th align="center" rowspan="1" colspan="1">ARDSNet</th><th align="center" rowspan="1" colspan="1">p value</th><th align="center" rowspan="1" colspan="1">ART</th><th align="center" rowspan="1" colspan="1">ARDSNet</th><th align="center" rowspan="1" colspan="1">p value</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Tidal volume (mL/kg of predicted body weight)</td><td align="center" rowspan="1" colspan="1">x.x &#x000b1; x.x</td><td align="center" rowspan="1" colspan="1">x.x &#x000b1; x.x</td><td align="center" rowspan="1" colspan="1">x.xx</td><td align="center" rowspan="1" colspan="1">x.x &#x000b1; x.x</td><td align="center" rowspan="1" colspan="1">x.x &#x000b1; x.x</td><td align="center" rowspan="1" colspan="1">x.xx</td><td align="center" rowspan="1" colspan="1">x.x &#x000b1; x.x</td><td align="center" rowspan="1" colspan="1">x.x &#x000b1; x.x</td><td align="center" rowspan="1" colspan="1">x.xx</td><td align="center" rowspan="1" colspan="1">x.x &#x000b1; x.x</td><td align="center" rowspan="1" colspan="1">x.x &#x000b1; x.x</td><td align="center" rowspan="1" colspan="1">x.xx</td></tr><tr><td align="left" rowspan="1" colspan="1">Tidal volume &#x0003e; 6.5mL/kg of predicted body
weight, N/total N (%)</td><td align="center" rowspan="1" colspan="1">x/x (x.x)</td><td align="center" rowspan="1" colspan="1">x/x (x.x)</td><td align="center" rowspan="1" colspan="1">x.xx</td><td align="center" rowspan="1" colspan="1">x/x (x.x)</td><td align="center" rowspan="1" colspan="1">x/x (x.x)</td><td align="center" rowspan="1" colspan="1">x.xx</td><td align="center" rowspan="1" colspan="1">x/x (x.x)</td><td align="center" rowspan="1" colspan="1">x/x (x.x)</td><td align="center" rowspan="1" colspan="1">x.xx</td><td align="center" rowspan="1" colspan="1">x/x (x.x)</td><td align="center" rowspan="1" colspan="1">x/x (x.x)</td><td align="center" rowspan="1" colspan="1">x.xx</td></tr><tr><td align="left" rowspan="1" colspan="1">PEEP (cmH<sub>2</sub>O)</td><td align="center" rowspan="1" colspan="1">x.x &#x000b1; x.x</td><td align="center" rowspan="1" colspan="1">x.x &#x000b1; x.x</td><td align="center" rowspan="1" colspan="1">x.xx</td><td align="center" rowspan="1" colspan="1">x.x &#x000b1; x.x</td><td align="center" rowspan="1" colspan="1">x.x &#x000b1; x.x</td><td align="center" rowspan="1" colspan="1">x.xx</td><td align="center" rowspan="1" colspan="1">x.x &#x000b1; x.x</td><td align="center" rowspan="1" colspan="1">x.x &#x000b1; x.x</td><td align="center" rowspan="1" colspan="1">x.xx</td><td align="center" rowspan="1" colspan="1">x.x &#x000b1; x.x</td><td align="center" rowspan="1" colspan="1">x.x &#x000b1; x.x</td><td align="center" rowspan="1" colspan="1">x.xx</td></tr><tr><td align="left" rowspan="1" colspan="1">Plateau pressure (cmH<sub>2</sub>O)</td><td align="center" rowspan="1" colspan="1">x.x &#x000b1; x.x</td><td align="center" rowspan="1" colspan="1">x.x &#x000b1; x.x</td><td align="center" rowspan="1" colspan="1">x.xx</td><td align="center" rowspan="1" colspan="1">x.x &#x000b1; x.x</td><td align="center" rowspan="1" colspan="1">x.x &#x000b1; x.x</td><td align="center" rowspan="1" colspan="1">x.xx</td><td align="center" rowspan="1" colspan="1">x.x &#x000b1; x.x</td><td align="center" rowspan="1" colspan="1">x.x &#x000b1; x.x</td><td align="center" rowspan="1" colspan="1">x.xx</td><td align="center" rowspan="1" colspan="1">x.x &#x000b1; x.x</td><td align="center" rowspan="1" colspan="1">x.x &#x000b1; x.x</td><td align="center" rowspan="1" colspan="1">x.xx</td></tr><tr><td align="left" rowspan="1" colspan="1">Plateau pressure &#x0003e; 30cmH<sub>2</sub>O, N/total N
(%)</td><td align="center" rowspan="1" colspan="1">x/x (x.x)</td><td align="center" rowspan="1" colspan="1">x/x (x.x)</td><td align="center" rowspan="1" colspan="1">x.xx</td><td align="center" rowspan="1" colspan="1">x/x (x.x)</td><td align="center" rowspan="1" colspan="1">x/x (x.x)</td><td align="center" rowspan="1" colspan="1">x.xx</td><td align="center" rowspan="1" colspan="1">x/x (x.x)</td><td align="center" rowspan="1" colspan="1">x/x (x.x)</td><td align="center" rowspan="1" colspan="1">x.xx</td><td align="center" rowspan="1" colspan="1">x/x (x.x)</td><td align="center" rowspan="1" colspan="1">x/x (x.x)</td><td align="center" rowspan="1" colspan="1">x.xx</td></tr><tr><td align="left" rowspan="1" colspan="1">Driving pressure (cmH<sub>2</sub>O)</td><td align="center" rowspan="1" colspan="1">x.x &#x000b1; x.x</td><td align="center" rowspan="1" colspan="1">x.x &#x000b1; x.x</td><td align="center" rowspan="1" colspan="1">x.xx</td><td align="center" rowspan="1" colspan="1">x.x &#x000b1; x.x</td><td align="center" rowspan="1" colspan="1">x.x &#x000b1; x.x</td><td align="center" rowspan="1" colspan="1">x.xx</td><td align="center" rowspan="1" colspan="1">x.x &#x000b1; x.x</td><td align="center" rowspan="1" colspan="1">x.x &#x000b1; x.x</td><td align="center" rowspan="1" colspan="1">x.xx</td><td align="center" rowspan="1" colspan="1">x.x &#x000b1; x.x</td><td align="center" rowspan="1" colspan="1">x.x &#x000b1; x.x</td><td align="center" rowspan="1" colspan="1">x.xx</td></tr><tr><td align="left" rowspan="1" colspan="1">Respiratory system static compliance
(mL/cmH<sub>2</sub>O)</td><td align="center" rowspan="1" colspan="1">x.x &#x000b1; x.x</td><td align="center" rowspan="1" colspan="1">x.x &#x000b1; x.x</td><td align="center" rowspan="1" colspan="1">x.xx</td><td align="center" rowspan="1" colspan="1">x.x &#x000b1; x.x</td><td align="center" rowspan="1" colspan="1">x.x &#x000b1; x.x</td><td align="center" rowspan="1" colspan="1">x.xx</td><td align="center" rowspan="1" colspan="1">x.x &#x000b1; x.x</td><td align="center" rowspan="1" colspan="1">x.x &#x000b1; x.x</td><td align="center" rowspan="1" colspan="1">x.xx</td><td align="center" rowspan="1" colspan="1">x.x &#x000b1; x.x</td><td align="center" rowspan="1" colspan="1">x.x &#x000b1; x.x</td><td align="center" rowspan="1" colspan="1">x.xx</td></tr><tr><td align="left" rowspan="1" colspan="1">Respiratory rate (breaths/min)</td><td align="center" rowspan="1" colspan="1">x.x &#x000b1; x.x</td><td align="center" rowspan="1" colspan="1">x.x &#x000b1; x.x</td><td align="center" rowspan="1" colspan="1">x.xx</td><td align="center" rowspan="1" colspan="1">x.x &#x000b1; x.x</td><td align="center" rowspan="1" colspan="1">x.x &#x000b1; x.x</td><td align="center" rowspan="1" colspan="1">x.xx</td><td align="center" rowspan="1" colspan="1">x.x &#x000b1; x.x</td><td align="center" rowspan="1" colspan="1">x.x &#x000b1; x.x</td><td align="center" rowspan="1" colspan="1">x.xx</td><td align="center" rowspan="1" colspan="1">x.x &#x000b1; x.x</td><td align="center" rowspan="1" colspan="1">x.x &#x000b1; x.x</td><td align="center" rowspan="1" colspan="1">x.xx</td></tr><tr><td align="left" rowspan="1" colspan="1">PaO<sub>2</sub>/FIO<sub>2</sub></td><td align="center" rowspan="1" colspan="1">x.x &#x000b1; x.x</td><td align="center" rowspan="1" colspan="1">x.x &#x000b1; x.x</td><td align="center" rowspan="1" colspan="1">x.xx</td><td align="center" rowspan="1" colspan="1">x.x &#x000b1; x.x</td><td align="center" rowspan="1" colspan="1">x.x &#x000b1; x.x</td><td align="center" rowspan="1" colspan="1">x.xx</td><td align="center" rowspan="1" colspan="1">x.x &#x000b1; x.x</td><td align="center" rowspan="1" colspan="1">x.x &#x000b1; x.x</td><td align="center" rowspan="1" colspan="1">x.xx</td><td align="center" rowspan="1" colspan="1">x.x &#x000b1; x.x</td><td align="center" rowspan="1" colspan="1">x.x &#x000b1; x.x</td><td align="center" rowspan="1" colspan="1">x.xx</td></tr><tr><td align="left" rowspan="1" colspan="1">PaCO<sub>2</sub> (mmHg)</td><td align="center" rowspan="1" colspan="1">x.x &#x000b1; x.x</td><td align="center" rowspan="1" colspan="1">x.x &#x000b1; x.x</td><td align="center" rowspan="1" colspan="1">x.xx</td><td align="center" rowspan="1" colspan="1">x.x &#x000b1; x.x</td><td align="center" rowspan="1" colspan="1">x.x &#x000b1; x.x</td><td align="center" rowspan="1" colspan="1">x.xx</td><td align="center" rowspan="1" colspan="1">x.x &#x000b1; x.x</td><td align="center" rowspan="1" colspan="1">x.x &#x000b1; x.x</td><td align="center" rowspan="1" colspan="1">x.xx</td><td align="center" rowspan="1" colspan="1">x.x &#x000b1; x.x</td><td align="center" rowspan="1" colspan="1">x.x &#x000b1; x.x</td><td align="center" rowspan="1" colspan="1">x.xx</td></tr><tr><td align="left" rowspan="1" colspan="1">Arterial pH</td><td align="center" rowspan="1" colspan="1">x.x &#x000b1; x.x</td><td align="center" rowspan="1" colspan="1">x.x &#x000b1; x.x</td><td align="center" rowspan="1" colspan="1">x.xx</td><td align="center" rowspan="1" colspan="1">x.x &#x000b1; x.x</td><td align="center" rowspan="1" colspan="1">x.x &#x000b1; x.x</td><td align="center" rowspan="1" colspan="1">x.xx</td><td align="center" rowspan="1" colspan="1">x.x &#x000b1; x.x</td><td align="center" rowspan="1" colspan="1">x.x &#x000b1; x.x</td><td align="center" rowspan="1" colspan="1">x.xx</td><td align="center" rowspan="1" colspan="1">x.x &#x000b1; x.x</td><td align="center" rowspan="1" colspan="1">x.x &#x000b1; x.x</td><td align="center" rowspan="1" colspan="1">x.xx</td></tr></tbody></table><table-wrap-foot><fn id="TFN14"><p>ART - Alveolar Recruitment Trial; PEEP - positive end-expiratory
pressure; PaO<sub>2</sub> - partial pressure of arterial oxygen;
PaCO<sub>2</sub> - partial pressure of carbon dioxide Plus-minus
values are the means &#x000b1; standard deviation.</p></fn></table-wrap-foot></table-wrap><table-wrap id="t5" orientation="portrait" position="float"><label>Table 5</label><caption><p>Fluid balance, weight gain and co-interventions during the first seven
days of treatment</p></caption><table frame="hsides" rules="groups"><colgroup span="1"><col width="25%" span="1"/><col width="25%" span="1"/><col width="25%" span="1"/><col width="25%" span="1"/></colgroup><thead><tr><th align="left" rowspan="1" colspan="1">&#x000a0;</th><th align="center" rowspan="1" colspan="1">ARDSNET<break/> (n=x)</th><th align="center" rowspan="1" colspan="1">ART<break/> (n=x)</th><th align="center" rowspan="1" colspan="1">p value</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">24 hours fluid balance (mL)</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;Day 1</td><td align="center" rowspan="1" colspan="1">xx.x &#x000b1; xx.x</td><td align="center" rowspan="1" colspan="1">xx.x&#x000b1;xx.x</td><td align="center" rowspan="1" colspan="1">x.xx</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;Day 3</td><td align="center" rowspan="1" colspan="1">xx.x &#x000b1; xx.x</td><td align="center" rowspan="1" colspan="1">xx.x&#x000b1;xx.x</td><td align="center" rowspan="1" colspan="1">x.xx</td></tr><tr><td align="left" rowspan="1" colspan="1">Weight gain (kg)</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;Baseline to day 1</td><td align="center" rowspan="1" colspan="1">xx.x &#x000b1; xx.x</td><td align="center" rowspan="1" colspan="1">xx.x&#x000b1;xx.x</td><td align="center" rowspan="1" colspan="1">x.xx</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;Baseline to day 3</td><td align="center" rowspan="1" colspan="1">xx.x &#x000b1; xx.x</td><td align="center" rowspan="1" colspan="1">xx.x&#x000b1;xx.x</td><td align="center" rowspan="1" colspan="1">x.xx</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;Baseline to day 7</td><td align="center" rowspan="1" colspan="1">xx.x &#x000b1; xx.x</td><td align="center" rowspan="1" colspan="1">xx.x&#x000b1;xx.x</td><td align="center" rowspan="1" colspan="1">x.xx</td></tr><tr><td align="left" rowspan="1" colspan="1">Use of vasopressors, N/total N (%)</td><td align="center" rowspan="1" colspan="1">x/x (xx.x)</td><td align="center" rowspan="1" colspan="1">x/x (xx.x)</td><td align="center" rowspan="1" colspan="1">x.xx</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;Days of vasopressor use, median (IQR)</td><td align="center" rowspan="1" colspan="1">median (IQR)</td><td align="center" rowspan="1" colspan="1">median (IQR)</td><td align="center" rowspan="1" colspan="1">x.xx</td></tr><tr><td align="left" rowspan="1" colspan="1">Neuromuscular blockade, N/total N (%)</td><td align="center" rowspan="1" colspan="1">x/x (xx.x)</td><td align="center" rowspan="1" colspan="1">x/x (xx.x)</td><td align="center" rowspan="1" colspan="1">x.xx</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;Days of neuromuscular blocker use, median
(IQR)</td><td align="center" rowspan="1" colspan="1">median (IQR)</td><td align="center" rowspan="1" colspan="1">median (IQR)</td><td align="center" rowspan="1" colspan="1">x.xx</td></tr><tr><td align="left" rowspan="1" colspan="1">Sedative infusion, N/total N (%)</td><td align="center" rowspan="1" colspan="1">x/x (xx.x)</td><td align="center" rowspan="1" colspan="1">x/x (xx.x)</td><td align="center" rowspan="1" colspan="1">x.xx</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;Days of sedative infusion, median (IQR)</td><td align="center" rowspan="1" colspan="1">median (IQR)</td><td align="center" rowspan="1" colspan="1">median (IQR)</td><td align="center" rowspan="1" colspan="1">x.xx</td></tr><tr><td align="left" rowspan="1" colspan="1">Narcotic infusion, N/total N (%)</td><td align="center" rowspan="1" colspan="1">x/x (xx.x)</td><td align="center" rowspan="1" colspan="1">x/x (xx.x)</td><td align="center" rowspan="1" colspan="1">x.xx</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;Days of narcotic infusion, median (IQR)</td><td align="center" rowspan="1" colspan="1">median (IQR)</td><td align="center" rowspan="1" colspan="1">median (IQR)</td><td align="center" rowspan="1" colspan="1">x.xx</td></tr><tr><td align="left" rowspan="1" colspan="1">Use of corticosteroid, N/total N (%)</td><td align="center" rowspan="1" colspan="1">x/x (xx.x)</td><td align="center" rowspan="1" colspan="1">x/x (xx.x)</td><td align="center" rowspan="1" colspan="1">x.xx</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;Days of corticosteroid, median (IQR)</td><td align="center" rowspan="1" colspan="1">median (IQR)</td><td align="center" rowspan="1" colspan="1">median (IQR)</td><td align="center" rowspan="1" colspan="1">x.xx</td></tr><tr><td align="left" rowspan="1" colspan="1">Rescue therapies, N/total N (%)</td><td align="center" rowspan="1" colspan="1">x/x (xx.x)</td><td align="center" rowspan="1" colspan="1">x/x (xx.x)</td><td align="center" rowspan="1" colspan="1">x.xx</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;Prone position, N/total N (%)</td><td align="center" rowspan="1" colspan="1">x/x (xx.x)</td><td align="center" rowspan="1" colspan="1">x/x (xx.x)</td><td align="center" rowspan="1" colspan="1">x.xx</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;Inhaled nitric oxide, N/total N (%)</td><td align="center" rowspan="1" colspan="1">x/x (xx.x)</td><td align="center" rowspan="1" colspan="1">x/x (xx.x)</td><td align="center" rowspan="1" colspan="1">x.xx</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;High frequency oscillation, N/total N (%)</td><td align="center" rowspan="1" colspan="1">x/x (xx.x)</td><td align="center" rowspan="1" colspan="1">x/x (xx.x)</td><td align="center" rowspan="1" colspan="1">x.xx</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;Extracorporeal membrane oxygenation, N/total N
(%)</td><td align="center" rowspan="1" colspan="1">x/x (xx.x)</td><td align="center" rowspan="1" colspan="1">x/x (xx.x)</td><td align="center" rowspan="1" colspan="1">x.xx</td></tr></tbody></table><table-wrap-foot><fn id="TFN15"><p>ART - Alveolar Recruitment for ARDS Trial.</p></fn></table-wrap-foot></table-wrap></sec><sec><title>Effect on outcomes</title><p>We will report the number and percentage of deaths within 28 days after
randomization (<xref ref-type="table" rid="t6">Table 6</xref>). Survival within
28 days in both groups will be assessed using Kaplan-Meier curves, and hazard
ratios with a 95% confidence interval will be calculated with Cox proportional
hazard models without adjustment for other co-variates.</p><p>The two-sided &#x003b1;-level for the primary outcome final analysis is 0.042 to
account for alpha from the two interim analyses with boundaries at one-sided
&#x003b1; = 0.01.</p><p>We will extend the survival analysis until the 6-month follow-up and present the
results using Kaplan-Meier curves and the hazard ratio with a 95% confidence
interval, which will be calculated with Cox proportional hazard models. We will
also test proportional hazard assumptions and propose alternative parametric
survival models if the proportionality assumption is not sustained.<sup>(<xref rid="r11" ref-type="bibr">11</xref>)</sup></p><p>We will assess the effect of the intervention on ICU and in-hospital mortality
with risk ratios and 95% confidence intervals calculated with Wald's likelihood
ratio approximation test and with chi-squared tests for hypothesis testing. The
effects of the intervention on length of hospitalization, ICU stay and
ventilator-free days (until 28<sup>th</sup> day since randomization) will be
estimated with generalized linear models considering distributions that will fit
a possible heavy right-tailed distribution (such as <italic>gamma</italic>,
inverse <italic>Gaussian</italic>, or truncated <italic>Poisson</italic> for
ventilator-free days specifically), choosing the best fit according to the
model's deviance.<sup>(<xref rid="r12" ref-type="bibr">12</xref>)</sup></p><p>We will also address the effect of the intervention on the secondary safety
outcomes described in mock <xref ref-type="table" rid="t6">table 6</xref>. Every
comparison will be assessed by risk ratios with the respective 95%CI calculated
according to Wald's likelihood ratio approximation test.</p></sec><sec><title>Subgroup analyses</title><p>Treatment effects on 28-day mortality will be analyzed in the following
subgroups: (1) PaO<sub>2</sub>/FIO<sub>2</sub> &#x02264; 100
<italic>versus</italic> &#x0003e;100mmHg; (2) Simplified Acute Physiology Score
(SAPS) 3 score &#x0003c;50 <italic>versus</italic> &#x02265; 50; (3) pulmonary ARDS
<italic>versus</italic> extrapulmonary ARDS; (4) time of ARDS &#x02264; 36
hours <italic>versus</italic> &#x0003e; 36 to &#x0003c; 72 hours; (5) mechanical
ventilation &#x02264; 2 days; 3 to 4 days; &#x02265; 5 days; and (6) prone
position. Subgroups will be classified according to data obtained at baseline,
except for prone position, which will be classified according to the position
(prone or not prone) determined 1 hour after randomization. The reason for
considering 1-hour data for determining prone <italic>versus</italic> other
positions is because we have recommended to investigators that patients with an
indication for prone positioning should be moved to that position immediately
after randomization. The effects on subgroups will be evaluated according to the
interaction effects between each subgroup and the study arms by Cox proportional
hazard models.</p></sec><sec><title>Other exploratory analyses</title><p>We will test whether the effects of the intervention on the primary and secondary
outcomes are similar before and after the protocol amendment of June 2015.</p><p>As a sensitivity analysis, we will estimate the effect of the study intervention
on the primary outcome using Cox proportional hazard models with adjustment for
the following covariates determined at baseline: age, SAPS 3 score, and
PaO<sub>2</sub>/FIO<sub>2</sub>.</p><p>Finally, if there is evidence that the experimental treatment decreases 28-day
mortality, we should assess whether the driving pressure mediates the eventual
effects of the randomly assigned treatment on 28-day mortality. Mediators are
variables that are affected by treatment-group assignment and that subsequently
affect the outcome.<sup>(<xref rid="r13" ref-type="bibr">13</xref>)</sup>
Therefore, mediators are on the causal pathway of the relation between treatment
and outcome, at least partly explaining the effects of the treatment on the
outcome. In a first step, we plan to assess the effect of the driving pressure
determined on day 1 on 28-day mortality. This exploratory analysis will be
conducted using a Cox proportional hazard model adjusted for treatment
assignment (ART or ARDSNet), age, SAPS 3 score, and baseline
PaO<sub>2</sub>/FIO<sub>2</sub>. The effects of other respiratory variables
determined on day 1 (tidal volume, PEEP, plateau pressure, static compliance of
the respiratory system) on 28-day mortality will also be modeled by adding them
to the previously described Cox proportional hazard model.</p><p>In a second step, we will use the bootstrapping technique to test the mediation
models, an alternative to Baron and Kenny's causal steps model technique to
evaluate mediation.<sup>(<xref rid="r14" ref-type="bibr">14</xref>)</sup> We
will use the R package <italic>mediation</italic>.<sup>(<xref rid="r15" ref-type="bibr">15</xref>)</sup> These models will be adjusted for the
baseline tidal elastance of the respiratory system to avoid possible confounding
due to differences in the severity of the underlying respiratory illness. The
outputs of the mediation models will be the average causal mediation effect
(indirect effect) and direct effect. The indirect effect expresses the
proportion of the treatment effect occurring via the mediator, and the direct
effect expresses the proportion of the treatment effect that is independent of
the mediator.</p></sec><sec><title>Missing data</title><p>We anticipate no or minimal losses to follow-up for the primary and secondary
outcome data. We plan to carry out complete-case analyses for the primary and
secondary outcomes, that is, we will exclude patients with missing data.
However, if we end the trial with a loss of primary outcome data for 1% or more
of patients, we will carry out a sensitivity analysis using multiple imputation
techniques.</p></sec></sec><sec sec-type="conclusions"><title>CONCLUSION</title><p>According to the best trial practice, we report our statistical analysis plan and
data management plan prior to locking the database and starting analyses. We
anticipate that this document will prevent analysis bias and enhance the utility of
the reported results.</p></sec><sec><title>ACKNOWLEDGMENTS</title><p>Funded by the <italic>Programa de Apoio ao Desenvolvimento Institucional</italic> of
the <italic>Sistema</italic> &#x000da;nico <italic>de Sa&#x000fa;de</italic>
(PROADI-SUS) from the Brazilian Ministry of Health.</p></sec></body><back><fn-group><fn fn-type="COI-statement"><p><bold>Conflicts of interest:</bold> None.</p></fn><fn fn-type="other"><p><bold>Responsible editor:</bold> Thiago Costa Lisboa</p></fn></fn-group><ref-list><title>REFERENCES</title><ref id="r1"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gattinoni</surname><given-names>L</given-names></name><name><surname>Marini</surname><given-names>JJ</given-names></name><name><surname>Pesenti</surname><given-names>A</given-names></name><name><surname>Quintel</surname><given-names>M</given-names></name><name><surname>Mancebo</surname><given-names>J</given-names></name><name><surname>Brochard</surname><given-names>L</given-names></name></person-group><article-title>The "baby lung" became an adult</article-title><source>Intensive Care Med</source><year>2016</year><volume>42</volume><issue>5</issue><fpage>663</fpage><lpage>673</lpage><pub-id pub-id-type="pmid">26781952</pub-id></element-citation></ref><ref id="r2"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gattinoni</surname><given-names>L</given-names></name><name><surname>Protti</surname><given-names>A</given-names></name><name><surname>Caironi</surname><given-names>P</given-names></name><name><surname>Carlesso</surname><given-names>E</given-names></name></person-group><article-title>Ventilator-induced lung injury the anatomical and physiological
framework</article-title><source>Crit Care Med</source><year>2010</year><volume>38</volume><issue>10 Suppl</issue><fpage>S539</fpage><lpage>S548</lpage><pub-id pub-id-type="pmid">21164395</pub-id></element-citation></ref><ref id="r3"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Muscedere</surname><given-names>JG</given-names></name><name><surname>Mullen</surname><given-names>JB</given-names></name><name><surname>Gan</surname><given-names>K</given-names></name><name><surname>Slutsky</surname><given-names>AS</given-names></name></person-group><article-title>Tidal ventilation at low airway pressures can augment lung
injury</article-title><source>Am J Respir Crit Care Med</source><year>1994</year><volume>149</volume><issue>5</issue><fpage>1327</fpage><lpage>1334</lpage><pub-id pub-id-type="pmid">8173774</pub-id></element-citation></ref><ref id="r4"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Terragni</surname><given-names>PP</given-names></name><name><surname>Rosboch</surname><given-names>G</given-names></name><name><surname>Tealdi</surname><given-names>A</given-names></name><name><surname>Corno</surname><given-names>E</given-names></name><name><surname>Menaldo</surname><given-names>E</given-names></name><name><surname>Davini</surname><given-names>O</given-names></name><etal/></person-group><article-title>Tidal hyperinflation during low tidal volume ventilation in acute
respiratory distress syndrome</article-title><source>Am J Respir Crit Care Med</source><year>2007</year><volume>175</volume><issue>2</issue><fpage>160</fpage><lpage>166</lpage><pub-id pub-id-type="pmid">17038660</pub-id></element-citation></ref><ref id="r5"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Caironi</surname><given-names>P</given-names></name><name><surname>Cressoni</surname><given-names>M</given-names></name><name><surname>Chiumello</surname><given-names>D</given-names></name><name><surname>Ranieri</surname><given-names>M</given-names></name><name><surname>Quintel</surname><given-names>M</given-names></name><name><surname>Russo</surname><given-names>SG</given-names></name><etal/></person-group><article-title>Lung opening and closing during ventilation of acute respiratory
distress syndrome</article-title><source>Am J Respir Crit Care Med</source><year>2010</year><volume>181</volume><issue>6</issue><fpage>578</fpage><lpage>586</lpage><pub-id pub-id-type="pmid">19910610</pub-id></element-citation></ref><ref id="r6"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Suzumura</surname><given-names>EA</given-names></name><name><surname>Amato</surname><given-names>MB</given-names></name><name><surname>Cavalcanti</surname><given-names>AB</given-names></name></person-group><article-title>Understanding recruitment maneuvers</article-title><source>Intensive Care Med</source><year>2016</year><volume>42</volume><issue>5</issue><fpage>908</fpage><lpage>911</lpage><pub-id pub-id-type="pmid">26289012</pub-id></element-citation></ref><ref id="r7"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Borges</surname><given-names>JB</given-names></name><name><surname>Okamoto</surname><given-names>VN</given-names></name><name><surname>Matos</surname><given-names>GF</given-names></name><name><surname>Caramez</surname><given-names>MP</given-names></name><name><surname>Arantes</surname><given-names>PR</given-names></name><name><surname>Barros</surname><given-names>F</given-names></name><etal/></person-group><article-title>Reversibility of lung collapse and hypoxemia in early acute
respiratory distress syndrome</article-title><source>Am J Respir Crit Care Med</source><year>2006</year><volume>174</volume><issue>3</issue><fpage>268</fpage><lpage>278</lpage><pub-id pub-id-type="pmid">16690982</pub-id></element-citation></ref><ref id="r8"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>de Matos</surname><given-names>GF</given-names></name><name><surname>Stanzani</surname><given-names>F</given-names></name><name><surname>Passos</surname><given-names>RH</given-names></name><name><surname>Fontana</surname><given-names>MF</given-names></name><name><surname>Albaladejo</surname><given-names>R</given-names></name><name><surname>Caserta</surname><given-names>RE</given-names></name><etal/></person-group><article-title>How large is the lung recruitability in early acute respiratory
distress syndrome a prospective case series of patients monitored by
computed tomography</article-title><source>Crit Care</source><year>2012</year><volume>16</volume><issue>1</issue><fpage>R4</fpage><lpage>R4</lpage><pub-id pub-id-type="pmid">22226331</pub-id></element-citation></ref><ref id="r9"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Suzumura</surname><given-names>EA</given-names></name><name><surname>Figueir&#x000f3;</surname><given-names>M</given-names></name><name><surname>Normilio-Silva</surname><given-names>K</given-names></name><name><surname>Laranjeira</surname><given-names>L</given-names></name><name><surname>Oliveira</surname><given-names>C</given-names></name><name><surname>Buehler</surname><given-names>AM</given-names></name><etal/></person-group><article-title>Effects of alveolar recruitment maneuvers on clinical outcomes in
patients with acute respiratory distress syndrome a systematic review and
meta-analysis</article-title><source>Intensive Care Med</source><year>2014</year><volume>40</volume><issue>9</issue><fpage>1227</fpage><lpage>1240</lpage><pub-id pub-id-type="pmid">25097070</pub-id></element-citation></ref><ref id="r10"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><collab>ART Investigators</collab></person-group><article-title>Rationale, study design, and analysis plan of the Alveolar
Recruitment for ARDS Trial (ART) study protocol for a randomized controlled
trial</article-title><source>Trials</source><year>2012</year><volume>13</volume><fpage>153</fpage><lpage>153</lpage><pub-id pub-id-type="pmid">22929542</pub-id></element-citation></ref><ref id="r11"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Grambsch</surname><given-names>PM</given-names></name><name><surname>Therneau</surname><given-names>TM</given-names></name></person-group><article-title>Proportional hazards tests and diagnostics based on weighted
residuals</article-title><source>Biometrika</source><year>1994</year><volume>81</volume><issue>3</issue><fpage>515</fpage><lpage>526</lpage></element-citation></ref><ref id="r12"><label>12</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>McCullagh</surname><given-names>P</given-names></name><name><surname>Nelder</surname><given-names>JA</given-names></name></person-group><source>Generalized linear models</source><edition>2nd ed</edition><comment>(Monographs on Statistics and Probability 37)</comment><publisher-loc>London</publisher-loc><publisher-name>Chapman &#x00026; Hall</publisher-name><year>1989</year></element-citation></ref><ref id="r13"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shrout</surname><given-names>PE</given-names></name><name><surname>Bolger</surname><given-names>N</given-names></name></person-group><article-title>Mediation in experimental and nonexperimental studies new
procedures and recommendations</article-title><source>Psychol Methods</source><year>2002</year><volume>7</volume><issue>4</issue><fpage>422</fpage><lpage>445</lpage><pub-id pub-id-type="pmid">12530702</pub-id></element-citation></ref><ref id="r14"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Preacher</surname><given-names>KJ</given-names></name><name><surname>Hayes</surname><given-names>AF</given-names></name></person-group><article-title>Asymptotic and resampling strategies for assessing and comparing
indirect effects in multiple mediator models</article-title><source>Behav Res Methods</source><year>2008</year><volume>40</volume><issue>3</issue><fpage>879</fpage><lpage>891</lpage><pub-id pub-id-type="pmid">18697684</pub-id></element-citation></ref><ref id="r15"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tingley</surname><given-names>D</given-names></name><name><surname>Yamamoto</surname><given-names>T</given-names></name><name><surname>Hirose</surname><given-names>K</given-names></name><name><surname>Keele</surname><given-names>L</given-names></name><name><surname>Imai</surname><given-names>K</given-names></name></person-group><article-title>Mediation R package for causal mediation analysis</article-title><source>J Stat Software</source><year>2014</year><volume>59</volume><issue>5</issue><fpage>1</fpage><lpage>38</lpage></element-citation></ref></ref-list></back></article>